Michael L Friedlander

36PUBLICATIONS

375CO-AUTHORS

Molecular targetsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classified

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (36)

Sort by Publication Date:

|Jul 10, 2026

Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.

|Jul 06, 2026

Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies.

|Apr 01, 2026

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Tibor A Zwimpfer, Sian Fereday, Ahwan Pandey

|Jan 14, 2026

Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology Registry.

Mahendra Naidoo, Orla McNally, Clare L Scott

|Nov 19, 2025

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Dale Garsed, Tibor Zwimpfer, Sian Fereday

|Nov 05, 2025

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Chee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound

Pageof 6

Frequent Collaborators

Kelly-Anne Phillips

Paul Cohen

Roger Milne

Anna DeFazio

Clare Scott

Beth Y Karlan

Peter Fasching

Chee Khoon Lee

Martin Köbel

Dale W Garsed

Frequent Collaborators

Kelly-Anne Phillips

Paul Cohen

Roger Milne

Anna DeFazio